Health & Biotech

Microsoft's MAI-DxO scores 83% on NEJM cases; doctors 36%

The Frontier

Microsoft's MAI-DxO scores 83% on NEJM cases; doctors 36%

Microsoft's diagnostic system cleared peer review today. The interesting part is not the multiple in the headline — it is which doctors you compare it to, and how much of the win belongs to the model underneath rather than to Microsoft's orchestration. Microsoft's MAI-DxO answered 83% of 304 complex case records from the New England Journal of Medicine correctly, against 36% for primary care doctors who had textbooks and the internet, according to results published in Science on Thursday.

Stuart Russell: current training may make AI alignment impossible

The Guardrails

Stuart Russell: current training may make AI alignment impossible

A safety-obsessed week just found its second heavyweight: after Hinton asked for an FDA of AI, the man who gave the field the word "alignment" says the current road may not get there at all — while memory markets show exactly where the AI money is going. Stuart Russell says he regrets coining the word "alignment," because the field read it as an engineering target — and he now thinks the way models are trained today may make avoiding misalignment impossible.

The Take — An AI FDA would approve the demo, not the deployment

The Guardrails

The Take — An AI FDA would approve the demo, not the deployment

I think Geoffrey Hinton has the diagnosis right and the prescription backwards. Self-policing genuinely has no burden of proof — nobody outside a lab must be shown anything before a frontier model ships — and that has to change. But an FDA-style pre-market gate would certify the wrong object: a frozen snapshot presented on approval day, when every failure we have actually watched arrive did so afterward, through permissions, updates and tool access. Our morning brief laid out the ask from…

Hinton wants an FDA-style approval gate for AI models

The Guardrails

Hinton wants an FDA-style approval gate for AI models

A safety proposal with the field's most famous name behind it, a first hard look at who actually pays for consumer AI, and a new bet on squeezing more compute out of data centers that already exist. Geoffrey Hinton wants AI models to clear a regulator the way drugs clear the FDA. The Nobel laureate made the case on Tuesday's "Smart Girl Dumb Questions" podcast: "You're not allowed to just make a new drug and release it on the market. You have to convince the FDA.

RFK Jr. says AI gives a better second opinion than any doctor

The Guardrails

RFK Jr. says AI gives a better second opinion than any doctor

Two stories worth your time before the wire fills up with DevDay follow-ups: the US health secretary's new position on who Americans should trust for medical advice, and China's biggest assistant turning into a travel agent the day before Golden Week. Health Secretary Robert F. Kennedy Jr. told a MAHA summit audience that AI can give patients "a second opinion that is much better informed than any doctor in the country," and claimed it has the power to "free us from medical tyranny." Kennedy…

Insilico's AI-designed drug enters Phase III — a first for the field

The Frontier

Insilico's AI-designed drug enters Phase III — a first for the field

A drug whose target was found by AI and whose molecule was designed by AI is now in a late-stage trial — and the registry, not the press release, is what makes it a milestone. The same day brought a machine-checked maths result from a team of agents, and a brain-implant round with an unusual lead investor. Insilico Medicine has begun dosing patients in a 320-person Phase III trial of rentosertib, an oral treatment for idiopathic pulmonary fibrosis — the first drug with both an AI-identified…

Get SiliconNoon in your inbox

One email a day with the AI stories that matter — what happened, the numbers, and why it matters. No spam, unsubscribe in one click.